Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
20 01 2021
Historique:
received: 10 10 2020
accepted: 04 01 2021
entrez: 21 1 2021
pubmed: 22 1 2021
medline: 25 8 2021
Statut: epublish

Résumé

A recent study found serum neurofilament light chain (NfL) levels to be strongly associated with poor neurological outcome in patients after cardiac arrest. Our aim was to confirm these findings in an independent validation study and to investigate whether NfL improves the prognostic value of two cardiac arrest-specific risk scores. This prospective, single-center study included 164 consecutive adult after out-of-hospital cardiac arrest (OHCA) patients upon intensive care unit admission. We calculated two clinical risk scores (OHCA, CAHP) and measured NfL on admission within the first 24 h using the single molecule array NF-light Poor neurological outcome (CPC > 3) was found in 60% (98/164) of patients, with 55% (91/164) dying within 30 days of hospitalization. Compared to patients with favorable outcome, NfL was 14-times higher in patients with poor neurological outcome (685 ± 1787 vs. 49 ± 111 pg/mL), with an adjusted odds ratio of 3.4 (95% CI 2.1 to 5.6, p < 0.001) and an area under the curve (AUC) of 0.82. Adding NfL to the clinical risk scores significantly improved discrimination of both the OHCA score (from AUC 0.82 to 0.89, p < 0.001) and CAHP score (from AUC 0.89 to 0.92, p < 0.05). Adding NfL to both scores also resulted in significant improvement in reclassification statistics with a Net Reclassification Index (NRI) of 0.58 (p < 0.001) for OHCA and 0.83 (p < 0.001) for CAHP. Admission NfL was a strong outcome predictor and significantly improved two clinical risk scores regarding prognostication of neurological outcome in patients after cardiac arrest. When confirmed in future outcome studies, admission NfL should be considered as a standard laboratory measures in the evaluation of OHCA patients.

Sections du résumé

BACKGROUND
A recent study found serum neurofilament light chain (NfL) levels to be strongly associated with poor neurological outcome in patients after cardiac arrest. Our aim was to confirm these findings in an independent validation study and to investigate whether NfL improves the prognostic value of two cardiac arrest-specific risk scores.
METHODS
This prospective, single-center study included 164 consecutive adult after out-of-hospital cardiac arrest (OHCA) patients upon intensive care unit admission. We calculated two clinical risk scores (OHCA, CAHP) and measured NfL on admission within the first 24 h using the single molecule array NF-light
RESULTS
Poor neurological outcome (CPC > 3) was found in 60% (98/164) of patients, with 55% (91/164) dying within 30 days of hospitalization. Compared to patients with favorable outcome, NfL was 14-times higher in patients with poor neurological outcome (685 ± 1787 vs. 49 ± 111 pg/mL), with an adjusted odds ratio of 3.4 (95% CI 2.1 to 5.6, p < 0.001) and an area under the curve (AUC) of 0.82. Adding NfL to the clinical risk scores significantly improved discrimination of both the OHCA score (from AUC 0.82 to 0.89, p < 0.001) and CAHP score (from AUC 0.89 to 0.92, p < 0.05). Adding NfL to both scores also resulted in significant improvement in reclassification statistics with a Net Reclassification Index (NRI) of 0.58 (p < 0.001) for OHCA and 0.83 (p < 0.001) for CAHP.
CONCLUSIONS
Admission NfL was a strong outcome predictor and significantly improved two clinical risk scores regarding prognostication of neurological outcome in patients after cardiac arrest. When confirmed in future outcome studies, admission NfL should be considered as a standard laboratory measures in the evaluation of OHCA patients.

Identifiants

pubmed: 33472689
doi: 10.1186/s13054-021-03459-y
pii: 10.1186/s13054-021-03459-y
pmc: PMC7819224
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

32

Subventions

Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10001C_192850/1
Pays : International
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 10531C_182422
Pays : International
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 320030_189140/1
Pays : International
Organisme : Gottfried und Julia Bangerter-Rhyner-Stiftung
ID : 8472/HEG-DSV
Pays : International

Références

Intensive Care Med. 2015 Dec;41(12):2039-56
pubmed: 26464394
Int J Cardiol. 2013 Sep 30;168(2):1322-7
pubmed: 23287695
Sci Rep. 2016 Nov 07;6:36791
pubmed: 27819296
N Engl J Med. 2009 Aug 6;361(6):605-11
pubmed: 19657124
Intensive Care Med. 2015 Dec;41(12):2204-6
pubmed: 26464395
Resuscitation. 2019 Jun;139:214-221
pubmed: 31022497
Resuscitation. 2019 Sep;142:50-60
pubmed: 31306716
Neurology. 2018 Jan 2;90(1):e22-e30
pubmed: 29212830
JAMA Neurol. 2019 Jan 1;76(1):64-71
pubmed: 30383090
Stroke. 2009 Oct;40(10):3393-5
pubmed: 19679846
J Am Coll Cardiol. 2015 May 19;65(19):2104-14
pubmed: 25975474
Resuscitation. 2015 Oct;95:1-80
pubmed: 26477410
Stroke. 2019 Jul;50(7):1669-1675
pubmed: 31138085
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Lancet Neurol. 2016 May;15(6):597-609
pubmed: 27017468
Curr Neurol Neurosci Rep. 2019 Nov 13;19(11):90
pubmed: 31720870
Resuscitation. 2014 Feb;85(2):227-32
pubmed: 24231570
Crit Care. 2017 Apr 13;21(1):96
pubmed: 28410590
Circulation. 2014 Nov 18;130(21):1868-75
pubmed: 25399395
Neurology. 2017 Mar 7;88(10):930-937
pubmed: 28179466
Resuscitation. 2019 Mar;136:21-29
pubmed: 30391369
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
J Crit Care. 2019 Jun;51:57-63
pubmed: 30745287
Eur J Neurol. 2018 Mar;25(3):562-568
pubmed: 29281157
Nat Commun. 2020 Feb 10;11(1):812
pubmed: 32041951
Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12
pubmed: 17569110
Lancet. 1975 Mar 1;1(7905):480-4
pubmed: 46957
Crit Care. 2010;14(2):R69
pubmed: 20403168
Resuscitation. 2011 Aug;82(8):1036-40
pubmed: 21524837
Crit Care. 2012 Dec 12;16(2):R45
pubmed: 22410303
Neurology. 2011 Aug 16;77(7):623-30
pubmed: 21775743
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82
pubmed: 26472996
Resuscitation. 2018 Sep;130:138-145
pubmed: 30036589
Intensive Care Med. 2021 Jan;47(1):39-48
pubmed: 32852582
Crit Care Med. 2011 Jul;39(7):1670-4
pubmed: 21494106
Neurology. 2018 Oct 2;91(14):e1338-e1347
pubmed: 30217937
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Resuscitation. 2009 Feb;80(2):165-70
pubmed: 18954930
Eur Heart J. 2016 Nov 07;37(42):3222-3228
pubmed: 26497161
Eur Heart J. 2006 Dec;27(23):2840-5
pubmed: 17082207

Auteurs

Sabina Hunziker (S)

Intensive Care Unit, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. Sabina.Hunziker@usb.ch.
Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland. Sabina.Hunziker@usb.ch.
Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland. Sabina.Hunziker@usb.ch.

Adrian Quinto (A)

Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland.

Maja Ramin-Wright (M)

Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland.

Christoph Becker (C)

Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland.

Katharina Beck (K)

Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland.

Alessia Vincent (A)

Medical Communication and Psychosomatic Medicine, University Hospital Basel, Klingelbergstrasse 23, 4031, Basel, Switzerland.

Kai Tisljar (K)

Intensive Care Unit, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.

Giulio Disanto (G)

Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

Pascal Benkert (P)

Clinical Trial Unit Basel, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.

David Leppert (D)

Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

Hans Pargger (H)

Intensive Care Unit, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.

Stephan Marsch (S)

Intensive Care Unit, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.
Intensive Care Unit, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Division of Clinical Neurophysiology, Department of Neurology, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.

Nils Peters (N)

Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

Jens Kuhle (J)

Medical Faculty, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland.
Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH